Long-term morbidity risk low in patients with leukemia after allogeneic HCT
by Traci Bratton
Patients who received allogeneic hematopoietic cell transplantation to treat chronic myeloid leukemia demonstrated similar long-term morbidity rates as their siblings who did not have the disease, as well as the general population.